Questions About a Clinical Trial Evaluating the Addition of Cetuximab to Definitive Chemoradiation Therapy With Paclitaxel and Cisplatin for Patients With Esophageal Cancer-Reply
Overview
Overview
Journal
JAMA Oncol
Publisher
American Medical Association
Specialty
Oncology
Date
2018 Mar 30
PMID
29596545
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
van Hagen P, Hulshof M, van Lanschot J, Steyerberg E, van Berge Henegouwen M, Wijnhoven B
. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012; 366(22):2074-84.
DOI: 10.1056/NEJMoa1112088.
View
2.
Crosby T, Hurt C, Falk S, Gollins S, Mukherjee S, Staffurth J
. Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial. Lancet Oncol. 2013; 14(7):627-37.
DOI: 10.1016/S1470-2045(13)70136-0.
View
3.
Suntharalingam M, Winter K, Ilson D, Dicker A, Kachnic L, Konski A
. Effect of the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation Therapy for Patients With Esophageal Cancer: The NRG Oncology RTOG 0436 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2017; 3(11):1520-1528.
PMC: 5710193.
DOI: 10.1001/jamaoncol.2017.1598.
View